MX2020013614A - Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. - Google Patents

Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad.

Info

Publication number
MX2020013614A
MX2020013614A MX2020013614A MX2020013614A MX2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A
Authority
MX
Mexico
Prior art keywords
methods
onset
age
treating
preventing
Prior art date
Application number
MX2020013614A
Other languages
English (en)
Spanish (es)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MX2020013614A publication Critical patent/MX2020013614A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2020013614A 2018-06-13 2019-06-13 Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. MX2020013614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
PCT/US2019/036946 WO2019241503A1 (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Publications (1)

Publication Number Publication Date
MX2020013614A true MX2020013614A (es) 2021-05-27

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013614A MX2020013614A (es) 2018-06-13 2019-06-13 Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad.

Country Status (11)

Country Link
US (2) US20190381071A1 (cg-RX-API-DMAC7.html)
EP (1) EP3806862A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021527090A (cg-RX-API-DMAC7.html)
KR (1) KR20210009422A (cg-RX-API-DMAC7.html)
CN (1) CN112566641A (cg-RX-API-DMAC7.html)
AU (1) AU2019285065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020025296A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103463A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020013614A (cg-RX-API-DMAC7.html)
SG (1) SG11202012343TA (cg-RX-API-DMAC7.html)
WO (1) WO2019241503A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
AU2021446815B2 (en) * 2021-05-21 2025-09-11 Animuscure Inc. Composition comprising inotodiol for prevention or treatment of muscular disease
WO2025054408A1 (en) * 2023-09-07 2025-03-13 NeuroTherapia, Inc. Methods of treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
CA2985271A1 (en) * 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
BR112020025296A2 (pt) 2021-03-09
SG11202012343TA (en) 2021-01-28
JP2021527090A (ja) 2021-10-11
CA3103463A1 (en) 2019-12-19
KR20210009422A (ko) 2021-01-26
EP3806862A4 (en) 2022-07-06
WO2019241503A1 (en) 2019-12-19
EP3806862A1 (en) 2021-04-21
US20190381071A1 (en) 2019-12-19
US20210252023A1 (en) 2021-08-19
CN112566641A (zh) 2021-03-26
AU2019285065A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
EP4365179A3 (en) Novel rapamycin derivatives
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MY207223A (en) Prodrug modulators of the integrated stress pathway
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
GB2553252A8 (en) Compositions and methods for inhibiting factor D
SG11202012343TA (en) Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
WO2016130460A3 (en) Phthalazinone pyrazole derivatives for treating retinal degenerative disease
MX2021007247A (es) Derivados de rapamicina.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2024005310A (es) Composiciones para el tratamiento de la perdida del cabello.
PH12022550497A1 (en) Perk inhibiting compounds
PH12021552953A1 (en) Tricyclic compounds
WO2020049598A3 (en) Apalutamide polymorphs
EP3813872A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
EP4017873A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
SG11202105664VA (en) Methods of promoting healthy catch-up growth
MX2018010617A (es) Composición fungicida sinérgica para controlar fitoenfermedades.
HK40068687A (en) Compositions and methods for the treatment of kras associated diseases or disorders
HK40059398A (en) Methods of promoting healthy catch-up growth
MY208423A (en) Composition of aminopyran derivative